ValuEngine downgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a sell rating to a strong sell rating in a research report report published on Friday.
Other analysts have also recently issued research reports about the stock. Wedbush raised shares of Spark Therapeutics from an underperform rating to a neutral rating and reduced their target price for the company from $65.00 to $50.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. SunTrust Banks increased their price target on shares of Spark Therapeutics to $113.00 and gave the company a buy rating in a research note on Thursday, January 4th. BMO Capital Markets increased their price target on shares of Spark Therapeutics from $64.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, January 25th. Leerink Swann lowered shares of Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 price target on the stock. in a research note on Tuesday, December 12th. Finally, Raymond James Financial reiterated a buy rating on shares of Spark Therapeutics in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the stock. Spark Therapeutics currently has an average rating of Buy and an average price target of $75.18.
Shares of Spark Therapeutics (ONCE) opened at $54.83 on Friday. The firm has a market cap of $2,030.00, a P/E ratio of -7.62 and a beta of 3.02. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same period last year, the business earned ($1.07) EPS. research analysts predict that Spark Therapeutics will post -7.55 earnings per share for the current fiscal year.
In other news, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at $876,750. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,827 shares of company stock worth $3,118,519. Insiders own 7.30% of the company’s stock.
A number of large investors have recently bought and sold shares of ONCE. Gilder Gagnon Howe & Co. LLC purchased a new position in Spark Therapeutics in the 4th quarter valued at $28,188,000. Janus Henderson Group PLC purchased a new position in Spark Therapeutics in the 2nd quarter valued at $30,848,000. Orbimed Advisors LLC purchased a new position in Spark Therapeutics in the 3rd quarter valued at $38,340,000. Rockefeller Financial Services Inc. grew its position in Spark Therapeutics by 27,905.0% in the 4th quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock valued at $18,202,000 after buying an additional 352,719 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Spark Therapeutics in the 3rd quarter valued at $27,239,000. Hedge funds and other institutional investors own 94.57% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.